| Literature DB >> 34801512 |
Swati Dhasmana1, Anupam Dhasmana1, Acharan S Narula2, Meena Jaggi1, Murali M Yallapu1, Subhash C Chauhan3.
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurological disease affecting both upper and lower motor neurons. In the United States alone, there are 16,000-20,000 established cases of ALS. The early disease diagnosis is challenging due to many overlapping pathophysiologies with other neurological diseases. The etiology of ALS is unknown; however, it is divided into two categories: familial ALS (fALS) which occurs due to gene mutations & contributes to 5-10% of ALS, and sporadic ALS (sALS) which is due to environmental factors & contributes to 90-95% of ALS. There is still no curative treatment for ALS: palliative care and symptomatic treatment are therefore essential components in the management of these patients. In this review, we provide a panoramic view of ALS, which includes epidemiology, risk factors, pathophysiologies, biomarkers, diagnosis, therapeutics (natural, synthetic, gene-based, pharmacological, stem cell, extracellular vesicles, and physical therapy), controversies (in the clinical trials of ALS), the scope of nanomedicine in ALS, and future perspectives.Entities:
Keywords: Amyotrophic lateral sclerosis; Diagnosis; Nanomedicine; Neurological disorder; Pathophysiology; Therapeutics
Mesh:
Year: 2021 PMID: 34801512 DOI: 10.1016/j.lfs.2021.120156
Source DB: PubMed Journal: Life Sci ISSN: 0024-3205 Impact factor: 5.037